Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€13.80

€13.80

-1.430%
-0.2
-1.430%
-
 
09.01.26 / Frankfurt WKN: A40BDL / Name: Curatis Holding / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Curatis Holding

sharewise wants to provide you with the best news and tools for Curatis Holding, so we directly link to the best financial data sources.

News

Curatis Holding AG announces CHF 1.2 million private placement with strategic investor
Curatis Holding AG announces CHF 1.2 million private placement with strategic investor
Curatis Holding AG announces CHF 1.2 million private placement with strategic investor
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
Curatis: Double-digit growth in core business and
development milestone achieved for C-PTBE-01
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study